Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results.

Abstract

To evaluate the impact of the Epitomee capsule on quality of life (QOL) and its association with weight loss in adults with overweight and obesity. This study analyzed the RESET double-blind, placebo-controlled results, focusing on predefined QOL endpoints and post hoc analyses. A total of 279 participants with a BMI of 27-40 kg/m² were treated for 24 weeks with Epitomee or placebo, along with lifestyle intervention. Statistical analyses examined changes in IWQOL-Lite-CT scores, their relationship with weight loss, and subgroup differences. Compared to the placebo group, the Epitomee group consistently showed improved outcomes in total IWQOL-Lite-CT score and Physical Function sub-score (p < 0.05), as well as numerically higher improvements in the Physical and Psychosocial sub-scores, although these did not reach statistical significance. Both treatment groups showed a significant improvement (p < 0.05) from baseline in the IWQOL-Lite-CT total score, as well as in Physical, Physical Function, and Psychosocial sub-scores over the 24-week period. A stronger correlation between weight loss and QOL improvements was observed with Epitomee vs. placebo. The Epitomee capsule, with lifestyle intervention, is associated with IWQOL-Lite-CT improvement, highlighting its potential as an effective non-pharmaceutical adjunct to lifestyle intervention for enhancing health outcomes in individuals with overweight and obesity.